Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Masi

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2025
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONOM M Germani, V Heinemann, D Rossini, et al.
Cancer Medicine|March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trialsG Martini, D Ciardiello, V Famiglietti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 12, 2018
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONOE Dell'Aquila, C Cremolini, T Zeppola, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatmentF Rossari, D Lavacchi, E Alimenti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2019
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studiesF Marmorino, D Rossini, S Lonardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2025
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONOP Ciracì, M M Germani, F Pietrantonio, et al.
Science (New York, N.Y.)|January 28, 2016
Astronomy. ASASSN-15lh: A highly super-luminous supernovaSubo Dong, B J Shappee, J L Prieto, et al.
ESMO Open|June 18, 2021
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinomaI G Rapposelli, S Shimose, T Kumada, et al.
Nature|January 7, 2006
Charon's size and an upper limit on its atmosphere from a stellar occultationB Sicardy, A Bellucci, E Gendron, et al.
ESMO Open|November 30, 2021
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinibM Rimini, M Kudo, T Tada, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2025
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONOM M Germani, V Heinemann, D Rossini, et al.
Cancer Medicine|March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trialsG Martini, D Ciardiello, V Famiglietti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 12, 2018
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONOE Dell'Aquila, C Cremolini, T Zeppola, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatmentF Rossari, D Lavacchi, E Alimenti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2019
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studiesF Marmorino, D Rossini, S Lonardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2025
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONOP Ciracì, M M Germani, F Pietrantonio, et al.
Science (New York, N.Y.)|January 28, 2016
Astronomy. ASASSN-15lh: A highly super-luminous supernovaSubo Dong, B J Shappee, J L Prieto, et al.
ESMO Open|June 18, 2021
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinomaI G Rapposelli, S Shimose, T Kumada, et al.
Nature|January 7, 2006
Charon's size and an upper limit on its atmosphere from a stellar occultationB Sicardy, A Bellucci, E Gendron, et al.
ESMO Open|November 30, 2021
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinibM Rimini, M Kudo, T Tada, et al.
Pageof 14